When should trastuzumab be held or discontinued for cardiac toxicity?

Hold trastuzumab if: LVEF drops ≥10% from baseline AND falls below 50%, OR LVEF drops ≥16% from baseline regardless of absolute value. Recheck LVEF in 4–6 weeks. Resume if LVEF ≥50% and drop from baseline <15%. Permanently discontinue if LVEF fails to improve or symptomatic HF (NYHA III/IV) persists.

How should LVEF be monitored during trastuzumab therapy?

Baseline LVEF required before start. Monitoring every 3 months during treatment (every 6 weeks if borderline). Post-treatment surveillance: every 6 months for 2 years (high-risk patients: prior anthracyclines, cardiac comorbidities). Cardio-oncology consultation for LVEF <50% or symptomatic heart failure.

Trastuzumab Cardiac Monitoring Interval Calculator

Determine LVEF monitoring frequency and trastuzumab hold/discontinuation thresholds for HER2+ breast cancer treatment based on baseline LVEF, prior anthracycline exposure, and cardiac risk factors.

⚕ Clinical Disclaimer: These calculators are for educational and reference purposes only. Always verify results with qualified clinical judgment and current clinical guidelines. Do not use as a sole basis for medical decisions.

How It Works

Determine LVEF monitoring frequency and trastuzumab hold/discontinuation thresholds for HER2+ breast cancer treatment based on baseline LVEF, prior anthracycline exposure, and cardiac risk factors

Each component has a specific meaning:

Baseline LVEF — The baseline lvef recorded for the scenario being assessed.
Prior anthracycline exposure — The prior anthracycline exposure recorded for the scenario being assessed.
Cardiac risk factors — The cardiac risk factors recorded for the scenario being assessed.

Note: Interpret the trastuzumab cardiac monitoring result against the thresholds and context described above.

How to Use

Enter the baseline LVEF, prior anthracycline exposure, cardiac risk factors for the scenario you are assessing. Determine LVEF monitoring frequency and trastuzumab hold/discontinuation thresholds for HER2+ breast cancer treatment based on baseline LVEF, prior anthracycline exposure, and cardiac risk factors. Use the trastuzumab cardiac monitoring result to inform your calculation.

Related Calculators

Anthracycline Cardiac Risk

Medical Long-tail